Syndax Pharmaceuticals, Inc.
SNDX Real Time Price USDRecent trades of SNDX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SNDX's directors and management
Government lobbying spending instances
-
$20,000 Aug 12, 2020 Issue: Health Issues Government Issues
-
$80,000 Jul 19, 2020 Issue: Health Issues Government Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Selection of patients for combination therapy Jun. 04, 2024
-
Patent Title: Inhibitors of the menin-mll interaction Mar. 05, 2024
-
Patent Title: Selection of patients for combination therapy Jul. 26, 2022
-
Patent Title: Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer May. 10, 2022
-
Patent Title: Methods for the treatment of breast cancer Mar. 12, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SNDX in WallStreetBets Daily Discussion
Recent insights relating to SNDX
Recent picks made for SNDX stock on CNBC
ETFs with the largest estimated holdings in SNDX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SNDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.